Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous idiotype vaccine (Icon Genetics)
- Development stage
- Unknown
- Lead developer
- Icon Genetics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This autologous idiotype vaccine is a personalized immunotherapy developed by Icon Genetics for the treatment of relapsed follicular lymphoma. The vaccine is produced using the company's proprietary "magnifection" technology, which involves the transient expression of patient-specific immunoglobulin (idiotype) proteins in *Nicotiana benthamiana* plants. This plant-based expression system allows for the rapid and scalable production of individualized antigens, which are then purified and administered to the patient, typically alongside an adjuvant like GM-CSF. The mechanism of action involves stimulating the patient's immune system to recognize and attack the unique clonal B-cell receptors (idiotypes) present on the surface of their specific follicular lymphoma cells, thereby providing a highly targeted anti-tumor effect.
- Other names
- plant-derived autologous idiotype vaccinemagnifection-produced idiotype vaccineautologous FL vaccine
02
Targets
Id (Tumor-specific idiotype immunoglobulin)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on autologous idiotype vaccine (Icon Genetics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous idiotype vaccine (Icon Genetics).